Harrow Health Acquires Rights to 4 Branded Eye Drops
IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
In addition, the new findings show that co-treatment with KO-539 and the BCL2 inhibitor venetoclax induces synergistic activity in patient-derived AML cells expressing KMT2A rearrangements or NPM1 mutations, with or
Vermilion Energy To Acquire Equinor Energy Ireland For $434M
The Corrib Acquisition will add approximately 23 mmboe of 2P reserves and is expected to produce approximately 7,700 boe/d in 2022. Based on forward commodity prices, the Corrib Acquisition is forecast to generate approximately $365 million of FFO and $361 million of FCF in 2022 which equates to an FFO and FCF netback of approximately $130/boe.
Seven Oaks SPAC Announces Acquisition of MaxDelivery, a New York On-Demand Grocery Delivery Service
MaxDelivery provides New Yorkers with a fast, easy, and convenient way to have a broad assortment of groceries delivered directly to their door on-demand, through its one-hour delivery service in Manhattan. Since its
Kamada Acquires 4 FDA-Approved Commercial Products from Saol Therapeutics for $95M
CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) product indicated for the prophylaxis of cytomegalovirus disease associated with the transplantation of the kidney, lung,
Yumanity Therapeutics Q3 EPS $(0.97), Sales $1.64M
Yumanity Therapeutics (NASDAQ:YMTX) reported quarterly losses of $(0.97) per share. The company reported $1.64 million in sales this quarter.
Digimarc Q3 EPS $(0.48) Beats $(0.51) Estimate, Sales $6.42M Miss $6.44M Estimate
Digimarc (NASDAQ:DMRC) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 21.31 percent increase over losses of $(0.61) per share from the same
Priority Tech Holdings Q3 EPS $(0.83) Misses $(0.01) Estimate, Sales $132.50M Beat $126.36M Estimate
Priority Tech Holdings (NASDAQ:PRTH) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.01) by 8200 percent. This is a 388.24 percent decrease over losses of $(0.17) per
Tecnoglass Raises FY2021 Sales Guidance from $450.00M-465.00M to $485.00M-495.00M
Tecnoglass (NASDAQ:TGLS) raises FY2021 sales outlook from $450.00 million-465.00 million to $485.00 million-495.00 million.
Axsome Therapeutics Q3 EPS $(0.93) Beats $(0.95) Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(0.95) by 2.11 percent. This is a 52.46 percent decrease over losses of $(0.61) per share